Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cassava Sciences Inc

1.61
-0.0100-0.62%
Volume:435.09K
Turnover:707.13K
Market Cap:77.78M
PE:-1.10
High:1.67
Open:1.64
Low:1.60
Close:1.62
Loading ...

Sector Update: Health Care Stocks Edge Higher Premarket Monday

MT Newswires Live
·
25 Nov 2024

Cassava Sciences sinks 84% to $4.21 after Alzheimer’s study miss

TIPRANKS
·
25 Nov 2024

Traders Eye Fed Minutes, Key Inflation Metric as US Equity Futures Rise Pre-Bell

MT Newswires Live
·
25 Nov 2024

BUZZ-Cassava Sciences shares drop as Alzheimer's drug fails in late-stage study

Reuters
·
25 Nov 2024

Cassava plummets 86% as simufilam phase 3 Alzheimer's trial misses endpoints

seekingalpha
·
25 Nov 2024

Stock Track | Cassava Sciences Plunges 85% Pre-Market as Alzheimer's Drug Trial Fails to Meet Endpoints

Stock Track
·
25 Nov 2024

Cassava Sciences Shares Resume Trading Premarket, Last Down About 85% at $3.94 After Co's Alzheimer's Drug Failed in a Late-Stage Study

THOMSON REUTERS
·
25 Nov 2024

Cassava Sciences Simufilam Misses Endpoints in Late-Stage Alzheimer's Trial; Shares Drop Pre-Bell

MT Newswires Live
·
25 Nov 2024

Cassava Sciences' stock halted down 5% after Alzheimer's disease trial fails to meet its goals

Dow Jones
·
25 Nov 2024

Cassava Sciences' Alzheimer's Treatment Didn't Meet Endpoints in Study

Dow Jones
·
25 Nov 2024

Cassava announces Phase 3 ReThink-ALZ data did not meet co-primary endpoints

TIPRANKS
·
25 Nov 2024

Cassava's Alzheimer's drug fails in late-stage study

Reuters
·
25 Nov 2024

Cassava Sciences Inc: Simufilam Did Not Show a Significant Reduction in Cognitive or Functional Decline Versus Placebo

THOMSON REUTERS
·
25 Nov 2024

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

THOMSON REUTERS
·
25 Nov 2024

Cassava Sciences Inc: Simufilam Continued to Demonstrate an Overall Favorable Safety Profile

THOMSON REUTERS
·
25 Nov 2024

Cassava Sciences Inc: Also Be Discontinuing Open Label Extension Study

THOMSON REUTERS
·
25 Nov 2024

Cassava Sciences Inc: to Discontinue Refocus-Alz

THOMSON REUTERS
·
25 Nov 2024

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

GlobeNewswire
·
25 Nov 2024

Cassava Sciences Shares Halted for News Pending Premarket

THOMSON REUTERS
·
25 Nov 2024

Cassava Sciences to Hold Corporate Update on November 25th

GlobeNewswire
·
25 Nov 2024